Deficient expression of O6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma

Naohiko Kohya, Kohji Miyazaki, Shiroh Matsukura, Hiroyuki Yakushiji, Yoshihiko Kitajima, Kenji Kitahara, Masao Fukuhara, Yusaku Nakabeppu, Mutsuo Sekiguchi

研究成果: ジャーナルへの寄稿記事

52 引用 (Scopus)

抄録

Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that transfers methyl groups from O6-methylguanine to itself. Alkylation of DNA at the O6 position of guanine is an important step in the induction of mutations in the organism by alkylating agents. The O6-methyl G:T mismatch is recognized by the mismatch-repair (MMR) pathway. The biliary duct is highly exposed to alkylating agents because of its anatomical location. Methods: We examined 39 surgically resected gallbladder carcinomas and 35 extrahepatic bile duct carcinomas and evaluated the expression of MGMT and MMR protein (hMLH1 and hMSH2) by immunohistochemical staining. Results: MGMT-negative staining was detected in 59.0% of gallbladder carcinoma specimens and 60.0% of extrahepatic bile duct carcinoma specimens. In gallbladder carcinoma, hMLH1 and hMSH2-negative staining was observed in 51.3% and 59.0%, respectively, whereas in extrahepatic bile duct carcinoma, the respective values were 57.1% and 65.7%. MGMT-negative staining correlated with hepatic invasion in gallbladder carcinoma and with poor prognosis in both types of tumor. Furthermore, a combined MGMT and MMR status was shown to be a more significant prognostic biomarker in both tumor types. Conclusions: Combined MGMT and MMR is a possible prognostic marker that probably reflects an accumulation of genetic mutations.

元の言語英語
ページ(範囲)371-379
ページ数9
ジャーナルAnnals of Surgical Oncology
9
発行部数4
DOI
出版物ステータス出版済み - 5 21 2002

Fingerprint

DNA Mismatch Repair
Methyltransferases
Biliary Tract
Carcinoma
Gallbladder
Extrahepatic Bile Ducts
DNA
Negative Staining
Proteins
Alkylating Agents
DNA Repair Enzymes
Guanine
Alkylation
O-(6)-methylguanine
Neoplasms
Biomarkers
Staining and Labeling
Mutation
Liver

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

これを引用

Deficient expression of O6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. / Kohya, Naohiko; Miyazaki, Kohji; Matsukura, Shiroh; Yakushiji, Hiroyuki; Kitajima, Yoshihiko; Kitahara, Kenji; Fukuhara, Masao; Nakabeppu, Yusaku; Sekiguchi, Mutsuo.

:: Annals of Surgical Oncology, 巻 9, 番号 4, 21.05.2002, p. 371-379.

研究成果: ジャーナルへの寄稿記事

Kohya, Naohiko ; Miyazaki, Kohji ; Matsukura, Shiroh ; Yakushiji, Hiroyuki ; Kitajima, Yoshihiko ; Kitahara, Kenji ; Fukuhara, Masao ; Nakabeppu, Yusaku ; Sekiguchi, Mutsuo. / Deficient expression of O6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. :: Annals of Surgical Oncology. 2002 ; 巻 9, 番号 4. pp. 371-379.
@article{aa0df3da3b7a450983ac2d685a8c8dd9,
title = "Deficient expression of O6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma",
abstract = "Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that transfers methyl groups from O6-methylguanine to itself. Alkylation of DNA at the O6 position of guanine is an important step in the induction of mutations in the organism by alkylating agents. The O6-methyl G:T mismatch is recognized by the mismatch-repair (MMR) pathway. The biliary duct is highly exposed to alkylating agents because of its anatomical location. Methods: We examined 39 surgically resected gallbladder carcinomas and 35 extrahepatic bile duct carcinomas and evaluated the expression of MGMT and MMR protein (hMLH1 and hMSH2) by immunohistochemical staining. Results: MGMT-negative staining was detected in 59.0{\%} of gallbladder carcinoma specimens and 60.0{\%} of extrahepatic bile duct carcinoma specimens. In gallbladder carcinoma, hMLH1 and hMSH2-negative staining was observed in 51.3{\%} and 59.0{\%}, respectively, whereas in extrahepatic bile duct carcinoma, the respective values were 57.1{\%} and 65.7{\%}. MGMT-negative staining correlated with hepatic invasion in gallbladder carcinoma and with poor prognosis in both types of tumor. Furthermore, a combined MGMT and MMR status was shown to be a more significant prognostic biomarker in both tumor types. Conclusions: Combined MGMT and MMR is a possible prognostic marker that probably reflects an accumulation of genetic mutations.",
author = "Naohiko Kohya and Kohji Miyazaki and Shiroh Matsukura and Hiroyuki Yakushiji and Yoshihiko Kitajima and Kenji Kitahara and Masao Fukuhara and Yusaku Nakabeppu and Mutsuo Sekiguchi",
year = "2002",
month = "5",
day = "21",
doi = "10.1245/aso.2002.9.4.371",
language = "English",
volume = "9",
pages = "371--379",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Deficient expression of O6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma

AU - Kohya, Naohiko

AU - Miyazaki, Kohji

AU - Matsukura, Shiroh

AU - Yakushiji, Hiroyuki

AU - Kitajima, Yoshihiko

AU - Kitahara, Kenji

AU - Fukuhara, Masao

AU - Nakabeppu, Yusaku

AU - Sekiguchi, Mutsuo

PY - 2002/5/21

Y1 - 2002/5/21

N2 - Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that transfers methyl groups from O6-methylguanine to itself. Alkylation of DNA at the O6 position of guanine is an important step in the induction of mutations in the organism by alkylating agents. The O6-methyl G:T mismatch is recognized by the mismatch-repair (MMR) pathway. The biliary duct is highly exposed to alkylating agents because of its anatomical location. Methods: We examined 39 surgically resected gallbladder carcinomas and 35 extrahepatic bile duct carcinomas and evaluated the expression of MGMT and MMR protein (hMLH1 and hMSH2) by immunohistochemical staining. Results: MGMT-negative staining was detected in 59.0% of gallbladder carcinoma specimens and 60.0% of extrahepatic bile duct carcinoma specimens. In gallbladder carcinoma, hMLH1 and hMSH2-negative staining was observed in 51.3% and 59.0%, respectively, whereas in extrahepatic bile duct carcinoma, the respective values were 57.1% and 65.7%. MGMT-negative staining correlated with hepatic invasion in gallbladder carcinoma and with poor prognosis in both types of tumor. Furthermore, a combined MGMT and MMR status was shown to be a more significant prognostic biomarker in both tumor types. Conclusions: Combined MGMT and MMR is a possible prognostic marker that probably reflects an accumulation of genetic mutations.

AB - Background: O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that transfers methyl groups from O6-methylguanine to itself. Alkylation of DNA at the O6 position of guanine is an important step in the induction of mutations in the organism by alkylating agents. The O6-methyl G:T mismatch is recognized by the mismatch-repair (MMR) pathway. The biliary duct is highly exposed to alkylating agents because of its anatomical location. Methods: We examined 39 surgically resected gallbladder carcinomas and 35 extrahepatic bile duct carcinomas and evaluated the expression of MGMT and MMR protein (hMLH1 and hMSH2) by immunohistochemical staining. Results: MGMT-negative staining was detected in 59.0% of gallbladder carcinoma specimens and 60.0% of extrahepatic bile duct carcinoma specimens. In gallbladder carcinoma, hMLH1 and hMSH2-negative staining was observed in 51.3% and 59.0%, respectively, whereas in extrahepatic bile duct carcinoma, the respective values were 57.1% and 65.7%. MGMT-negative staining correlated with hepatic invasion in gallbladder carcinoma and with poor prognosis in both types of tumor. Furthermore, a combined MGMT and MMR status was shown to be a more significant prognostic biomarker in both tumor types. Conclusions: Combined MGMT and MMR is a possible prognostic marker that probably reflects an accumulation of genetic mutations.

UR - http://www.scopus.com/inward/record.url?scp=0036256948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036256948&partnerID=8YFLogxK

U2 - 10.1245/aso.2002.9.4.371

DO - 10.1245/aso.2002.9.4.371

M3 - Article

C2 - 11986189

AN - SCOPUS:0036256948

VL - 9

SP - 371

EP - 379

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -